u/marit_laurent

Same read. The energy-expenditure mechanism is the interesting bit and it is not established in humans at scale.

identity testing on a small molecule is a different analytical problem

The phase 2 readout ran to 48 weeks in a few hundred participants with a slow escalation. Both the size and the duration matter when people quote the headline number.

lyophilised powder is far more forgiving than the panic threads suggest

Cosigning on daily dosing. It changes the exposure profile and it changes adherence, in both directions.

That is the ambient temperature at the destination, not the temperature inside the box. The logger measures the second one.

Powder or already in solution?

Buying small from an unfamiliar supplier and testing before committing is the single procedural change that would have prevented the largest share of financial losses described on this board.

How long have you been logging?

Spent an evening with the appendix tables and found the subgroup detail that the entire thread had been speculating about.

nobody gets judged here, that is the entire premise

A beyond-use date derived from published stability data means something different from one assigned by default rule. Asking which is a fair question and the answer is usually available.

How many days in transit, and which month?

a mean is not a promise

first_hundred is right about the programme names. They are different populations with different endpoints.

oral and non-peptide is the whole engineering story

lyophilised powder is far more forgiving than the panic threads suggest

if you want to know, log it, otherwise you are guessing

transit temperature is a distribution, not a number

Are you comparing the same presentation, or different pack sizes?

the glucagon component is why the metabolic story reads differently

Compounded preparations are not approved products and carry no bioequivalence claim. That is a statement about regulatory category, not about quality.

That figure is the starting material purity, not the finished preparation potency. Two different tests.

What did the intake actually ask you?

That is the ambient temperature at the destination, not the temperature inside the box. The logger measures the second one.

Careful with that mean. The distribution around it was wide enough that it describes very few individual participants.

How fast was the escalation? That is usually the variable that explains the reports.

Gel packs are designed for a duty cycle. A liquid pack at the end of a longer-than-expected transit is a pack behaving as specified, not evidence of an excursion in the vial.

What lead time were you quoted for that line?

Contemporaneous records do not drift; reconstructed ones do, and the drift is systematic rather than random because memory smooths.

teodor_szabo is right about blanks. Silent gaps make the series lie.

a telehealth intake that asks nothing has told you what it is

Yes. Nothing in this catalogue is approved for human use and the board should keep saying so.

Cosigning on missed weeks. Leaving them blank makes the whole series misleading.

Are you comparing against phase 3 numbers for something else? They are not comparable.

Nothing containing this compound is approved by any regulator, and research-use-only material is not approved for human use.

Agreed. The 503A versus 503B distinction changes who is allowed to make what, and almost every confused thread here starts by ignoring it.

Agreed — identity first for anything off the well-travelled list.

Agreed — and the naming problem is worse than most people here realise.

Wrote the reconstitution date on the vial for the first time last year. Have never once since wondered how old a solution is.

log what you did, not what you meant to do

this board exists so the failures are on the record too

Small fix — those rules apply to commercial import. Personal import is governed separately and more narrowly.